Clinical Trials
114 trialsRegorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]
M.D. Anderson Cancer Center
Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Tislelizumab and Regorafenib as First-Line Therapy for Advanced Cholangiocarcinoma
The First Affiliated Hospital of Zhengzhou University
TAPUR
American Society of Clinical Oncology
REVIVE
Asan Medical Center
REGINA
Jules Bordet Institute
PARERE
Gruppo Oncologico del Nord-Ovest
MIRAGE
Istituto Oncologico Veneto IRCCS
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
University of Miami
Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment
Peking University Cancer Hospital & Institute
Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC.
Sun Yat-sen University
MegaMOST
Centre Leon Berard
RELEVANT-HCC
Asan Medical Center
RECOMEND
Asan Medical Center
EREMISS
Centre Oscar Lambret
REGO-SARC
Centre Oscar Lambret
Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib
Wake Forest University Health Sciences
DREAM
First Affiliated Hospital, Sun Yat-Sen University
A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer
Memorial Sloan Kettering Cancer Center
A Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR/MSS Localized Rectal Cancer
M.D. Anderson Cancer Center
Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer
University of Pittsburgh
Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.
M.D. Anderson Cancer Center
Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer
National Cancer Institute, Naples
SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma
Sarcoma Alliance for Research through Collaboration
REGOBONE
UNICANCER
A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer
Dana-Farber Cancer Institute
Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Memorial Sloan Kettering Cancer Center
ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST
University of Miami
Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer
Academic and Community Cancer Research United
5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer
The Methodist Hospital Research Institute
Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer
Case Comprehensive Cancer Center
LEAF-02
Fudan University
Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line Treatment
Tianjin Medical University Cancer Institute and Hospital
Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
Academic and Community Cancer Research United
Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma
Case Comprehensive Cancer Center
Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC
Fudan University
x-МАР
Pavlov First Saint Petersburg State Medical University
SED-RO-ICC
Shanghai Zhongshan Hospital
The Aim of This Study is to Assess the Efficacy and Safety of Chidamide, Regorafenib in Combination With Iparomlimab and Tuvonralimab for the Treatment of Advanced Colorectal Cancer in Third-line Therapy and Subsequent Lines.
Shanghai Changzheng Hospital
SOREGATT
UNICANCER
Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC
Humanity & Health Medical Group Limited
a-MANTRA
Gruppo Oncologico Italiano di Ricerca Clinica
Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis
Fudan University
THYMI
Beijing Friendship Hospital
CARE
Centre Hospitalier Universitaire de Besancon
REPROGRAM-01
Centre Hospitalier Universitaire de Besancon
Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer
City of Hope Medical Center
Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer
Academic and Community Cancer Research United
SLOT
Fudan University
Regorafenib in Metastatic Colorectal Cancer
University of Rochester